research@rzst.org

RZST

Shattering the 99% Attrition Crisis: Grounding Federated Causal Logic in Human Microphysioology.

1. **Institutional Sovereignty:** Utilizing D-CLEF Network Topology
2. **The Causal Engine:** FedECA Causal Inference & IPTW Bias Neutralization
3. **The Empirical Anchor:** Closing the Loop with Patient-Derived Organ-on-a-Chip
4. **Accelerated Velocity:** Achieving Statistically Pure Predictive Baselines



| Open-Source Architectural Blueprint | Fully Aligned with 2026 FDA/EMA Joint AI Principles



This document serves as an open-architectural blueprint to synchronize global research without the cost and risk of data pooling. By integrating AI-driven simulations with Organ-on-a-Chip validation, this proposal outlines a high-fidelity, mathematically testable path from *in-silico* hypothesis to physical clinical reality—overseen by Human-in-the-Loop governance to ensure every step is grounded in real-world safety and logic. This framework is submitted not for commercial acquisition, but for rigorous peer review, regulatory audit, and systemic validation.

Architectural Note: Simulation Status & Validation Scope

The frameworks, workflows, and predictive baselines described in this proposal outline a high-fidelity in-silico blueprint—a rigorous computational simulation designed to precede and accelerate physical integration. While live clinical trials and physical Organ-on-a-Chip deployments represent the targeted operational phase, the current architectures operate strictly as stateful, mathematical frameworks. We maintain a "Zero-Data-Contact" policy at this stage, ensuring HIPAA and GDPR integrity by design before a single byte of live patient data is engaged. This theoretical blueprint is presented strictly for peer review, stress testing, and systemic validation prior to its execution in gold-standard clinical environments.

The Proposed Blueprint: Architecture & Synthesis

A comprehensive deep-dive into this proposed stateful orchestration framework and its flagship translational medicine proof-of-concept—from the core architectural engine and validation matrix to the multi-vector approach, *in-silico* rigor, and peer review stress tests.

High-fidelity logic for a low-patience world.

Note: You may scroll to read the full architectural dossier below, or download it as a PDF here.

Sovereignty & Ethics: The Non-Extractive Interface

The RZST blueprint recognizes that the inclusion of rural, tribal, and historically marginalized populations requires a fundamental shift in data governance. To align with federal CARE Principles for Indigenous Data Governance, the framework proposes a strictly non-extractive model: we architecturally propose to "Interface, Not Integrate."

I. Tribal Data Sovereignty & The Sovereign Vault

- **Health History Protection:** The simulated framework is engineered to ensure that all sensitive patient health history and genomic data remain permanently locked within the community's local, impenetrable data silos.

II. Zero-Data-Contact & Equitable Synthesis

- **The D-CLEF Protocol (Kuo et al., 2025):** The blueprint proposes utilizing the decentralized network topology of D-CLEF to achieve absolute "Zero-Data-Contact." Raw data never leaves institutional or tribal firewalls; only validated mathematical

- **Local Control:** By design, the architecture prevents the unauthorized extraction or centralized “pooling” of datathat has historically alienated Indigenous and rural communities. Sovereignty is mathematically maintained at the source.

abstractions transfer across the orchestration hub.

- **The FedECA Core (Owkin / du Terrail et al., 2025):** To ensure that insights from smaller sovereign nodes are not marginalized by larger urban hospitals, the architecture relies on the FedECA causal inference engine. This mathematics ensures equitable representation and bias neutralization without requiring data exposure.

The mathematical proofsunderpinning these sovereignty claims— including the IPTW propensity score weighting and FedAvg aggregationprotocol — are available for independent audit in the Technical Vault.

The Orchestration Engine: Synthesizing Validated Models

At the core of this architecture is a stateful multi-agent orchestration layer that fuses two distinct, peer-reviewed methodologies.

1. **The Network:** We deploy the **D-CLEF** architecture (Distributed Cross-Learning for Equitable Federated models), a decentralized, privacy-preserving framework pioneered by Kuo et al. (2025).
2. **The Mathematics:** We integrate the **FedECA** causal inference methodology, recently validated by Owkin (du Terrail et al., 2025), which utilizes Inverse Probability of Treatment Weighting (IPTW) in distributed settings.

This synthesis is not a probabilistic guess; it is a mathematical mandate. By fusing D-CLEF's secure routing with FedECA's causal logic, the framework proves the statistical honesty of the data without ever exposing the underlying patient records. The engine functions as a closed-loop execution pipeline, utilizing **Directed Acyclic Graphs (DAGs)** to enforce strict, unidirectional computational pathways. This topological constraint physically prevents algorithmic hallucination or trajectory drift; the data can only move forward through pre-approved logic gates.

The Validation Matrix: Auditing Systemic Viability

To ensure these architectural deployments mathematically optimize both real-world efficacy and health economics, the engine evaluates every proposal across four orthogonal axes:

[Axis I] Capital Optimization (Zero-CapEx Design)

This blueprint minimizes the physical and financial resources required for validation. By filtering out high-failure models early with decentralized compute, we mathematically optimize the pipeline's Energy Return on Investment.

[Axis II] Data Sovereignty (The LoRA Federation)

Utilizing Kuo's D-CLEF network principles, this architecture processes horizontally-partitioned data without extracting sensitive records. We simulate the local freezing of foundation models, federating only the Low-Rank Adaptation (LoRA) matrices. By transmitting only the mathematical pattern (the weight updates) rather than the raw data payload, this architecture establishes low-latency, privacy-preserving intelligence transfers via Parameter-Efficient Fine-Tuning (PEFT) while strictly preserving institutional firewalls.

[Axis III] Algorithmic Equity & Statistical Anonymity

Ending the era of "Geography as Destiny" in clinical research. This framework dismantles the structural bias inherent in centralized data pooling. By simulating Owkin's IPTW methodologies strictly behind local firewalls, we ensure the predictive baseline reflects true population diversity rather than localized hospital demographics. This statistical anonymity neutralizes selection bias before model training occurs, ensuring outputs are mathematically fair and scientifically valid for all patient populations.

[Axis IV] Longitudinal Provenance & State Maintenance

We design architectures intended for long-term strategic foresight. These stateful frameworks guarantee robust longitudinal data provenance and Architectural Readiness for ISTAND Integration. This ensures the theoretical framework is structurally prepared for stringent FDA and EMA regulatory audits before physical trials commence.

Collaborative Intelligence: ”Governed Autonomy”

This blueprint does not propose an unsupervised, black-box methodology. The architecture relies on an absolute division of labor through **"Governed Autonomy."**

Humans-in-the-loop act as the definitive regulatory firewall by setting strict biological and physical constraints *before* the multi-agent framework executes the computational heavy lifting. The AI cannot generate hypotheses that violate the laws of nature because human domain experts lock the parameters prior to execution, preventing trajectory drift at the source.

Blueprint for Grounded Medicine

The Four-Step Pipeline

How this framework orchestrates artificial intelligence for complex protein-based diseases, including ALS and Lewy Body Dementia.

The Architectural Synthesis

The engine acts as the master orchestrator. This blueprint is the first to integrate established **D-CLEF data networking**, **FedECA causal logic**, and multi-scale **Protein Language Models (PLMs)** to ground computational predictions within rigorous biological constraints.

Step 01

Privacy isn’t a policy; it’s the architecture.

Raw medical data remains secure within localized hospital “silos.” Before any intelligence traverses the network, it undergoes rigorous Local Validation. The data is mathematically cleaned and structurally validated at the localized source. Only this validated mathematical knowledge is transmitted, preserving patient sovereignty and preventing the propagation of corrupted or “noisy” data across the network.

Attribution: Utilizing D-CLEF Network Topology (Kuo et al., 2025)

Step 02

Causal rigor for a chaotic world.

The blueprint operates as the ultimate Bias Filter. It applies causal rigor locally before knowledge is shared, mathematically isolating the true mechanisms driving neurodegeneration. By enforcing this causal framework, the architecture explicitly prevents the AI from “hallucinating” false correlations or tracking localized noise, ensuring that only biologically sound insights move forward.

Attribution: Synthesizing FedECA causal logic (Owkin / du Terrail et al., 2025)

Step 03

Decoding the language of life's smallest failures.

A multi-agent panel coordinates knowledge synthesis, constructing multi-scale protein models to identify viable therapeutic pathways for targeted protein aggregates. This step is governed by strict Biological Constraints. The multi-agent panel operates entirely within the physical laws of nature established by the Human-in-the-Loop, physically preventing stochastic guesswork when mapping highly disordered proteins.

Focus: ALS (TDP-43) and LBD (Alpha-Synuclein)

Step 04

Closing the loop between AI and Anatomy.

The architecture plans for a future-state physical loop closure, acting as the ultimate Reality Check. By comparing *in-silico* AI predictions with physical Organ-on-a-Chip (OoC) readouts, an error vector is generated to backpropagate knowledge and continuously calibrate the model. Overcoming the "Transcriptomic Mismatch" serves as the critical validation bridge, proving definitively that the *in-silico* mathematics hold up against living, physical human biology.

Overcoming the "Transcriptomic Mismatch" Challenge

⚠ SIMULATED PIPELINE (IN-SILICO SIMULATION) — NO LIVE PHYSICAL TRIALS COMPLETED — PROPOSED FUTURE STATE

AI in Translational Medicine

To demonstrate the potential of this architecture, it was immediately directed to resolving systemic capital inefficiencies in neurodegenerative pipelines— a domain chosen precisely because it represents the most regulated, most ethically complex, and most data-siloed environment on earth. If the blueprint works here, it works anywhere.

This flagship architecture unifies the **D-CLEF Architecture (Distributed Cross-Learning for Equitable Federated models)** pioneered by Kuo et al. (2025), illustrating the framework's capacity to handle the most highly regulated data on earth—pending future physical validation.

The LoRA Bypass

The architecture refactors standard federated learning by simulating the local freezing of foundation models and transmitting only Low-Rank Adaptation (LoRA) matrices. This establishes low-latency, privacy-preserving intelligence transfers via Parameter-Efficient Fine-Tuning (PEFT) to bypass hospital IT bottlenecks.

The Causal-Privacy Breakthrough

By simulating Inverse Probability of Treatment Weighting (IPTW)—as established by du Terrail et al. (Owkin, 2025)—strictly behind local firewalls, agents generate bias-corrected causal insights without violating HIPAA or extracting raw patient records.

Accelerating Pipeline Velocity

Aggregating these simulated insights generates a mathematically pure predictive baseline (FedECA), drastically accelerating the timeline to reach gold-standard physical clinical trials for ALS and Lewy Body Dementia while maintaining absolute GDPR/HIPAA compliance.

The Architectural Synthesis Proposal

We are proposing a computational architecture designed for resolving systemic capital inefficiencies in neurodegenerative pipelines and the years lost navigating pre-clinical phases. This proposed blueprint drastically accelerates the timeline to reach gold-standard physical clinical trials.

To achieve this, we have engineered an *in-silico* pipeline that fuses two state-of-the-art frameworks. First, we deploy the **D-CLEF** (Distributed Cross-Learning for Equitable Federated models) network, a privacy-preserving decentralized architecture pioneered by Kuo et al. (2025). Second, we operationalize the **FedECA** methodology—recently validated by Owkin (du Terrail et al., 2025) in *Nature Communications*—to generate synthetic predictive baselines using Inverse Probability of Treatment Weighting (IPTW).

The Novelty: Here is where we push the boundary. Owkin proved FedECA works for standard oncology covariates. We are the first to combine Kuo's network with Owkin's math, and deploy it specifically for target proteinopathies using Multi-scale Protein Language Models. Furthermore, we solve the biological "black box" problem with a pipeline that bridges these federated insights directly into future *in-vitro* physical validation using Organ-on-a-Chip technologies. With this design, the blueprint connects decentralized computational frameworks directly to generative biological models.

A Multi-Vector Approach

The following vectors represent the blueprint architecture:

Vector I: Generation (The Silicon Substrate & Biological Grounding)

Utilizing multi-scale Protein Language Models (PLMs) operating on the silicon substrate to transform stochastic discovery into high-probability, biologically-grounded molecular design.

Vector II: Architected Deployment (The Physical Bridges)

Architecting the deployment of dynamic, federated computational networks (D-CLEF) designed for leading academic hubs. This framework generates Federated Predictive Baselines (FedECA) to mathematically de-risk pre-clinical assets, ensuring only the most viable candidates enter human testing. This establishes the blueprint for The Empirical Anchor: Validating AI-driven hypotheses through high-fidelity, patient-derived microphysiological readouts.

Vector III: Macro-Systems & Complex Infrastructure

The recursive pattern-process dynamics utilized to model micro-biological protein folding operate on identical mathematical principles at the macroscopic scale- Ensuring future applications are modeled distributed infrastructural enhancement. By applying strictly validated phase space analytics, we can scale closed-loop optimization architectures to broader macro-infrastructural systems.

In-Silico Rigor: Predictive Mathematical Blueprints

Before physical execution in decentralized networks or wet-labs, all architectures must undergo extreme computational and statistical validation. By validating all *in-silico* processes through rigorous statistical and cross-validation analysis, all outputs are mathematically sound and economically optimized before any physical capital is deployed.

A NOTE TO THE READER

While you navigate this new era of medical architecture, remember: A powerful engine is only as good as the conscience steerin' it. RZST isn't just about the math; it's about the mission.

Our Values: Grounded in Sovereignty, Equity, & Governance

While this engine operates at the forefront of stateful multi-agent orchestration and decentralized infrastructure, the foundational principles remain deeply rooted in regulatory compliance, data sovereignty, and equitable access. Through operationalizing ethical constraints into architectural advantages, the future of computational discovery empowers and protects all participants.

Institutional Data Sovereignty (The LoRA Imperative)

This architecture is designed to uphold the fundamental right of institutions, enterprises, and individuals to secure their own data. All federated computational models respect HIPAA, GDPR, and corporate firewalls by 'moving the intelligence' to the data. Utilizing the D-CLEF network principles pioneered by Kuo et al. (2025) and Parameter-Efficient Fine-Tuning (PEFT), this architecture federates only Low-Rank Adaptation (LoRA) matrices, ensuring that sensitive raw information is never extracted into vulnerable, centralized cloud silos.

Algorithmic Equity & Bias Mitigation

Sytematically mitigating algorithmic bias at the computational level, is non-negotiable. By simulating the IPTW causal inference techniques established by du Terrail et al. (Owkin, 2025) strictly behind local firewalls, this architecture neutralizes selection bias and confounding variables *before* neural network training occurs. This ensures the architecture generates equitable, causally-sound insights that accurately reflect marginalized or underrepresented populations.

Pipeline Acceleration & IND De-Risking (FedECA)

To systematically address the temporal and financial limitations of early-stage drug development: this architecture is a pursuit of Federated Predictive Baselines—building upon the methodology validated by Owkin (du Terrail et al., 2025)— and is driven by an economic and scientific imperative to reduce the timeline of medicine generation for neurodegenerative trials (ALS, Lewy Body Dementia). By generating a mathematically pure synthetic baseline, this architecture aims to elevate the statistical confidence of pre-clinical data packages prior to IND submission.

Human-in-the-Loop (HITL) Governance

This architecture is designed to enforce strict algorithmic governance. The 'engine' is not a black-box replacement for human insight; it is a collaborative, stateful orchestration layer. The goal is to ensure that human researchers and domain experts remain the definitive regulatory bottleneck—interpreting outputs, enforcing physical constraints, and preventing the trajectory drift and systemic errors inherent in unsupervised multi-agent systems.

Longitudinal Provenance & Auditability

With the future in mind, this architecture is engineered for long-term strategic foresight, not short-term data extraction. **Immutable Auditability:** Utilizing tools like Directed Acyclic Graphs to ensure regulatory-grade provenance for all AI-generated insights, providing absolute alignment with stringent regulatory pathways (e.g., FDA ISTAND and EMA guidelines). This architectural blueprint mitigates downstream systemic risks through transparent, reproducible auditing.

Closing the Computational Loop

Proposed Translation of Digital Twins to Physical Microphysiological Systems

Resolving the Efficacy Attrition Crisis: Grounding In-Silico Hypotheses in Human Microphysiological Readouts

The traditional pharmaceutical pipeline is constrained by a significant “translational gap”. Experimental compounds that demonstrate perfect binding affinities in computer simulations or exceptional efficacy in legacy animal models frequently fail during human clinical trials. In complex neurodegenerative diseases, this failure rate approaches 99%. To solve this, the engineering of this architecture focuses on de-risking the pipeline by substituting high-failure animal models with human-centric MPS.

The Convergent Horizon: Synthesizing AI and Microfluidics

While the current architecture represents a rigorously validated computational simulation based on the frameworks of Kuo et al. and du Terrail et al., the operational roadmap requires physical grounding. Creating a need to deploy a high-fidelity pipeline that directly couples the predictive outputs of Multi-scale Protein Language Models (PLMs) with living human biology.

1. **The Digital Output:** In the sequence, the federated PLM predicts the optimized molecular candidate with high-fidelity binding probability to selectively bind to toxic proteinopathies, such as fibrillar alpha-synuclein.

2. **Physical Synthesis & Integration:** The molecule is then physically synthesized and introduced into patient-derived Organ-on-a-Chip Microphysiological Systems (MPS).

3. **The Empirical Readout:** The microfluidic chip physically measures target engagement and screens for critical predictive toxicology (e.g., hepatotoxicity via DeepDILI, directly operationalizing the mandates of the FDA Modernization Act 2.0).

4. **Dynamic Calibration:** Backpropagating In-Vitro Loss Gradients to Refine Generative Molecular Design in a continuous loop.

Architecting for Mechanistic Proof

This closed-loop system is a regulatory necessity. Under the FDA's Plausible Mechanism Framework, marketing approval requires incontrovertible proof of target engagement. By grounding *in-silico* simulations with empirical *in-vitro* data from human microfluidics, the aim is to provide the exact mechanistic proof required by regulators. This architectural blueprint perfectly aligns with the NIH's July 2025 mandate to transition away from legacy animal testing, Establishing Mechanistic Proof: Bridging the In-Silico/In-Vitro Divide to Satisfy FDA 2026 Statutory Guidance.

The D-CLEF Lexicon: Proposed Mathematical Architecture

A Transparent, Rigorous Foundation for Federated Causal Inference

> *The orchestration layer operates on a fully transparent, mathematically rigorous theoretical foundation. We do not claim to have invented the base algorithms of federated learning or causal inference; rather, our breakthrough lies in the **Architectural Synthesis** of validated methodologies.*

I. Building on Validated Frameworks

The pipeline synthesizes two monumental achievements in recent computational biology:

1. **D-CLEF (Kuo et al., 2025):** A decentralized, privacy-preserving predictive modeling framework that operates without a single-point-of-control central server.
2. **FedECA (Owkin / du Terrail et al., 2025):** A federated extension of the Inverse Probability of Treatment Weighting (IPTW) method for estimating treatment effects on distributed time-to-event outcomes.

II. The Engineering Breakthrough: Synthesizing Federated Privacy with Causal Inference: A Unified Architectural Sequence

The legacy system assumes you can have privacy (via standard Federated Learning), *or* you can have causality (via centralized IPTW pooling), but you cannot have both. Building upon Owkin's foundational FedECA framework, we have to introduce an architectural sequence that explicitly bridges this gap for neurodegenerative diseases.

01

Localized Propensity Scoring

In our simulation, an algorithm within the localized, high-security institutional environment analyzes the raw patient data to calculate the propensity score—the probability that a specific patient received the experimental drug based on their baseline severity.

02

Generating a Bias-Corrected Pseudo-Population via Localized IPTW Execution

Still entirely behind the simulated firewall, the system applies the IPTW equations established by du Terrail et al. It mathematically weights the data, synthesizing a “Pseudo-Population” where treatment bias is theoretically flattened.

03

Secure Transmission via D-CLEF

Leveraging the decentralized, blockchain-backed architecture proposed by Kuo et al., the local node packages its learned causal insights into mathematical weight updates. It securely transmits only the loss gradients and weight deltas, ensuring rigorous de-identification via cryptographic abstraction.

04

Global Orchestration: Synchronizing Abstract Causal Gradients to Establish the FedECA Predictive Baseline

The network utilizes Federated Averaging to aggregate the data across all nodes:

$$\theta_{global}(t+1) = \sum_{k=1}^{K} (n_k / N) \cdot \theta_k(t+1)$$

θ_{global} — The Synthesized Global Predictive Model (The proposed FedECA Predictive Baseline)

θ_k — The isolated local model at simulated hospital node *k*

n_k / N — The weighting factor ensuring proportional representation across the network

We propose that θ_{global} becomes a statistically pure, bias-corrected Predictive Baseline derived entirely from decentralized data.

III. Temporal Compression: Utilizing In-Silico Baselines to Accelerate Clinical Entry (T=0)

In traditional development pipelines, reaching the starting line of a physical clinical trial (T=0) requires years of costly, high-failure empirical testing. In our theoretical architecture, we utilize *in-silico* baselines to accelerate this clinical entry.

> **We propose that θ_{global} becomes a statistically pure, bias-corrected pre-clinical baseline derived entirely from decentralized data.** By synthesizing these frameworks, we offer a blueprint to begin the next era of medicine: Exponential acceleration in the process of getting validated candidates into physical trials.

This is a rigorously defended mathematical theory of architectural viability and a software architecture blueprint, grounded in the Federated Averaging literature and the FedECA methodology validated by Owkin (du Terrail et al., 2025) in *Nature Communications*.

A NOTE TO THE READER

*Beyond the silicon and the sensors lies a new standard for translational medicine. We aren't just simulating data; we're architecting **hope** for the patients who can't afford to wait. Consider us farmers planting seeds meant to grow into Grounded Medicine for a Global Network.* 🌿

Access the Open-Source Synthesis

This architectural blueprint is an open-source architectural proposal. We offer this simulated synthesis of the D-CLEF network topology (Kuo et al., 2025) and FedECA causal mathematics (Owkin / du Terrail et al., 2025) as

a public good for the scientific community. Independent researchers, biostatisticians, and regulatory architects are encouraged to audit the logic, adapt the framework, or submit technical inquiries regarding our proposed *in-silico* pipeline.

Or reach us directly at **contact@rzst.org**

Architectural Resilience: Anticipatory Stress-Testing & Regulatory Alignment

Stress-Testing the Architecture: Anticipating the Hardest Questions

The following modules represent specific technical interrogations the blueprint will face from biostatisticians, FDA regulators, and GDPR/blockchain auditors. Each defense is the thought process of an **AI Methods Producer** operating under HITL Governed Autonomy.

Proposal-Stage Notice: *All responses below represent theoretical architectural defenses within a machine-learning simulated blueprint. No physical clinical trials or live deployments have been executed. The blueprint proposes; the AI Methods Producer defends the logic.*

Module I — Biostatistics

The FedECA & IPTW Stress Test

Unmeasured Covariate Drift & the Integrity of θ_{global}

The Attack

"IPTW is mathematically limited to balancing *measured* covariates (e.g., age, weight, known biomarkers). It cannot account for *unmeasured* confounding (e.g., localized hospital protocols, unrecorded patient habits, varying MRI calibration standards across the 22 CTSA nodes). If the engine is orchestrating decentralized weight updates via rigorous local validation (ΔW_k) without pooling the underlying data, how does the central global model (θ_{global}) detect and correct for unmeasured, site-specific covariate drift before it corrupts the simulated Predictive Baseline?"

The AI Methods Producer's Defense

Mitigating Unmeasured Confounding via High-Dimensional Latent Feature Extraction from Multi-Modal Data (PET/Transcriptomics)

Thesis: We neutralize unmeasured confounding by utilizing ultra-high-dimensional latent features as Biologically-Informed Surrogate Covariates.

The blueprint extracts these latent features from raw, localized data—including Yale PET center imaging and transcriptomic profiles via Cell2Sentence LLMs. These embeddings act as robust mathematical proxies for traditionally unmeasured clinical variables, substantially reducing the residual confounding that standard IPTW covariates cannot capture.

Simulated Sensitivity Analysis via E-Value Bounding

Thesis: We mathematically bound residual uncertainty to quantify trial validity.

The architecture integrates automated mathematical bounding—specifically E-value calculations—within the FedECA pipeline. This quantifies precisely how severe an unmeasured confounder would need to be to invalidate the simulated Predictive Baseline, providing a transparent, auditable threshold for regulatory review.

AI Methods Producer Note: No statistical framework eliminates unmeasured confounding. This defense establishes a mathematically rigorous bounding strategy, rendering residual uncertainty explicitly quantifiable and defensible under FDA and EMA audit standards.

Module II — Regulatory

The Organ-on-a-Chip & Systemic Efficacy Stress Test

Bridging Localized Chip Readouts to Full-Body Phase II

Neurodegenerative Efficacy

The Attack

"Under the FDA's 'Plausible Mechanism' framework... a chip simulating isolated tissue is not a systemic human being. While generating SMILES strings and predicting localized cellular toxicity is architecturally rigorous and regulatory-aligned, ALS and Lewy Body Dementia are systemic, multi-scale proteinopathies. How exactly does your simulated Quantitative Systems Pharmacology (QSP) model bridge the biological gap between a localized Organ-on-a-Chip readout and full-body, Phase II neurodegenerative efficacy?"

The AI Methods Producer's Defense

PBPK/QSP Bridging

Thesis: We utilize established, FDA-accepted quantitative pharmacology models to bridge micro-readouts to macro-efficacy.

The blueprint feeds localized chip readouts—cellular-level ground truth and localized loss gradients ($\nabla W_{\mathcal{L}}$) for toxicity—into advanced Physiologically Based Pharmacokinetic (PBPK) and Quantitative Systems Pharmacology (QSP) models. These are established regulatory-grade frameworks already accepted by the FDA for mechanistic bridging.

Systemic Extrapolation via Validated PBPK/QSP Frameworks and Generative Computational Cohorts

Thesis: Generative computational cohorts simulate whole-body biodistribution.

The architecture mathematically scales cellular data across these synthesized populations, simulating clearance rates and multi-organ interactions. This provides a scientifically plausible, computationally

> grounded bridge to systemic Phase II *in-silico* prediction—pending future physical validation.

AI Methods Producer Note: While PBPK/QSP models are established, FDA-accepted frameworks, RZST's breakthrough lies in the automated, federated coupling of chip-level empirical readouts to these systemic models at scale.

Module III — Systems Architecture

The GDPR Right-to-Erasure & Blockchain Stress Test

Salt Destruction, Orphaned Off-Chain Data, and FedAvg Integrity

The Attack
"If a patient exercises their GDPR right to erasure and you destroy the unique cryptographic salt, the off-chain clinical data is orphaned. In a decentralized, round-robin training cycle... does the engine force the D-CLEF network to lose network persistence and revert the FedAvg weights, or does the network continue training on a statistically skewed foundation?"

The AI Methods Producer's Defense

Irreversible Abstraction — GDPR Compliance by Architecture

Thesis: Destroying the cryptographic salt achieves legal erasure through mathematical irreversibility.

When a cryptographic salt is destroyed, it permanently severs all access to the raw off-chain data. This satisfies the GDPR right-to-erasure requirement at the architectural level—not through a policy promise, but through mathematical irreversibility. The data is not deleted; it is rendered permanently inaccessible, which is the legally equivalent outcome under GDPR Article 17.

Ensuring Statistical Stability and GDPR Compliance through Irreversible Gradient Abstraction

Thesis: Differential privacy renders aggregated weights completely anonymized, preserving network persistence.

> Historical weight updates (ΔW_k) are purely abstract mathematical gradients—not Personally Identifiable Information (PII). Once aggregated into θ_{global} with differential privacy noise applied, they cannot be reverse-engineered to recover individual patient data. A Stateful Multi-Agent Orchestration Layer is therefore designed to continue training without reverting, preserving both statistical stability and full legal compliance simultaneously.

AI Methods Producer Note: Grounded in differential privacy and GDPR Article 17, this blueprint legally classifies post-aggregation ΔW_k gradients as anonymized mathematical abstractions rather than personal data.

Engage with the Defense Architecture

This architecture demands interrogation from biostatisticians, regulatory scientists, and compliance architects. If you identify a stress test not addressed in this dossier, we are standing by.

Or reach us directly at **research@rzst.org**

RZST

Technical Vault

Mathematical & Cryptographic Proofs — Open Architectural Audit
This document is intended for federal data scientists, biostatisticians, and regulatory compliance architects conducting a rigorous structural review of the RZST proposed framework. All content is framed strictly as a computational simulation and architectural synthesis. No active clinical deployment is claimed or implied.

Architectural Attribution & Scope

A Synthesis, Not an Invention

RZST does not claim authorship of the foundational mathematics presented in this vault. This platform is engineered as an **architectural synthesis** of two independently peer-reviewed methodologies: the decentralized peer-to-peer network topology attributed to **D-CLEF (Kuo et al., 2025)**, and the federated causal inference mathematics attributed to **FedECA (Owkin / du Terrail et al., 2025)**. The contribution of this blueprint is the proposed orchestration layer that integrates these tools into a unified, governed, and regulatory-aligned simulation pipeline.

The three vaults below constitute an open mathematical and structural audit. Each section presents the underlying proof, the architectural implementation as proposed, and its alignment with applicable regulatory frameworks including GDPR Article 17 and the FDA 2026 Plausible Mechanism Framework.

VAULT A

The Biostatistical Proofs: Causal Rigor

Causal methodology attributed to **FedECA (Owkin / du Terrail et al., 2025)**

Proposed Mechanism: Federated Inverse Probability of Treatment Weighting (IPTW)

The proposed multi-agent orchestration layer is engineered to simulate Inverse Probability of Treatment Weighting (IPTW) behind local institutional firewalls. This design is intended to isolate true biological mechanisms and neutralize localized demographic bias without ever pooling raw patient data across institutional boundaries. The causal inference engine, as proposed, operates strictly on locally computed propensity scores, transmitting only aggregated mathematical abstractions across the D-CLEF network topology.

The IPTW propensity score weighting function assigns each simulated subject a weight inversely proportional to the probability of receiving their observed treatment, effectively constructing a pseudo-population in which treatment assignment is independent of measured confounders. For a binary treatment indicator Z_i and estimated propensity score $p_i = P(Z_i = 1 \mid X_i)$, the weight for subject i is defined as:

IPTW PROPENSITY SCORE WEIGHTING

$$w_i = \frac{Z_i}{p_i} + \frac{1 - Z_i}{1 - p_i}$$

In the proposed federated context, each participating institution computes p_i locally using its own patient cohort. The resulting weights are applied to local

outcome models before any gradient information leaves the institutional boundary. This architecture is designed to ensure that no raw covariate data, demographic identifiers, or treatment assignments are transmitted across the network at any stage of the simulation pipeline.

Federated Aggregation: The FedAvg Global Aggregation Protocol

Following local IPTW-weighted model training, the proposed orchestration layer is engineered to aggregate institutional model parameters using the Federated Averaging (FedAvg) protocol. Each participating node k contributes its locally trained parameter vector θ_k, weighted by the proportion of the total training population n_k/N it represents. The global model update is defined as:

FEDERATED AVERAGING (FEDAVG) GLOBAL AGGREGATION

$$\theta_{global} = \sum_{k=1}^{K} \frac{n_k}{N} \theta_k$$

AI Methods Producer Defense: E-Value Bounding

Vulnerability Addressed: Unmeasured Covariate Drift. Standard Inverse Probability of Treatment Weighting (IPTW) is inherently limited because it only balances *measured* variables, leaving the simulation vulnerable to hidden biases in diverse populations.

Proposed Structural Defense: To secure the simulated Virtual Control Arm, the orchestration extracts ultra-high-dimensional latent features (via Protein Language Models analyzing PET scans and transcriptomics) to act as surrogate covariates. To mathematically quantify any residual uncertainty, the engine proposes the application of **E-value bounding**. This calculates the minimum strength of association an unmeasured confounder would need to possess to negate the observed causal effect, thereby securing the FedECA-attributed baseline against selection bias.

where K denotes the total number of participating institutional nodes, n_k is the local sample size at node k, and $N = \sum_{k=1}^{K} n_k$ is the total aggregated sample size across the simulated network. This aggregation step is intended to occur exclusively on the central orchestration hub, which receives only the parameter vectors θ_k — not the underlying data from which they were derived. The resulting θ_{global} is then redistributed to all nodes for the subsequent training round.

> **Regulatory Note:** This simulated pipeline is designed to precede and accelerate physical integration. All IPTW and FedAvg computations described herein operate strictly as stateful mathematical frameworks. No live patient data is engaged at this stage of the proposed architecture.

VAULT B

The Sovereignty Proofs & GDPR Compliance

Decentralized network topology attributed to **D-CLEF (Kuo et al., 2025)**

Defense Against Quantum Encryption Obsolescence

The proposed architecture is engineered to anticipate the obsolescence of current asymmetric encryption standards under quantum computational threat models. The D-CLEF network topology, as synthesized in this blueprint, is designed to operate on a post-quantum cryptographic layer in which no single node retains the capacity to reconstruct the full dataset. Data sovereignty is maintained locally; only mathematically abstracted gradient updates (ΔW_k) are proposed for transmission across the peer-to-peer network. Because these transmitted objects are pure mathematical abstractions — not encrypted representations of raw data — they are architecturally immune to quantum decryption attacks that target ciphertext.

GDPR Article 17 Compliance: Mathematical Irreversibility via Cryptographic Salt Destruction

The proposed protocol for satisfying the GDPR "Right to Erasure" (Article 17) is grounded in the principle of **mathematical irreversibility** rather than conventional data deletion. The architecture proposes the following protocol:

01

Local Data Linkage via Cryptographic Salt

At the point of data ingestion, each patient record is linked to the local institutional node via a unique cryptographic salt. This salt is the sole mechanism by which the raw off-chain clinical data can be accessed or identified. It is generated locally and never transmitted across the D-CLEF network.

02

Pre-Transmission Salt Destruction

Before any aggregated weight updates (ΔW_k) are transmitted across the D-CLEF network, the local cryptographic salt linking the gradient data to the patient is permanently and irreversibly destroyed. This is not a soft deletion; it is a cryptographic operation that renders the underlying data permanently inaccessible by any computational means.

03

Classification as Non-PII Mathematical Abstractions

Following salt destruction, the transmitted weight updates ΔW_k are classified strictly as **non-PII mathematical abstractions**. They contain no recoverable patient identifiers, demographic data, or treatment assignments. Under GDPR Article 17, the legal obligation of erasure is satisfied at the architectural level — not through a policy promise, but through mathematical irreversibility. The data is not merely deleted; it is rendered permanently inaccessible, which constitutes the legally equivalent outcome.

04

Network Persistence & Statistical Stability

Once aggregated into θ_{global} with differential privacy noise applied, historical weight updates cannot be reverse-engineered to recover individual patient data. The proposed Stateful Multi-Agent Orchestration Layer is therefore engineered to continue training without reverting network weights upon a salt destruction event, preserving both statistical stability and full legal compliance simultaneously.

Compliance Note: This protocol is submitted as a proposed architectural design for peer review and regulatory audit. It is not presented as a certified compliance solution.

All claims regarding GDPR Article 17 equivalence are intended for stress-testing and scholarly interrogation by qualified legal and regulatory experts.

VAULT C

Biological Loop Closure & FDA Alignment

Proposed pathway toward alignment with the **FDA 2026 Plausible Mechanism Framework**

Proposed Pathway: From In-Silico Hypothesis to Physical Validation

The simulated blueprint maps a proposed pathway intended to align with the FDA 2026 Plausible Mechanism Framework. This framework requires that computational predictions be grounded in biologically plausible, mechanistically defensible models prior to clinical translation. The RZST architecture is engineered to eventually ingest localized cellular toxicity readouts from future patient-derived Organ-on-a-Chip microphysiological systems, pending the physical deployment phase of the proposed pipeline.

In the proposed architecture, local cellular readouts — including loss gradients ($\nabla W_{\mathcal{L}}$) representing localized toxicity signals at the chip level — are computationally fed into established regulatory-grade modeling frameworks. These readouts are intended for future *in-vitro* validation and are not derived from live clinical systems at the current simulation stage.

PBPK/QSP Integration: Scaling Cellular Data to Whole-Body Predictions

The proposed pipeline is designed to ingest localized cellular toxicity readouts ($\nabla W_{\mathcal{L}}$) from patient-derived Organ-on-a-Chip systems and computationally feed them into two established, FDA-accepted regulatory-grade modeling frameworks:

Physiologically Based Pharmacokinetic (PBPK) Modeling

PBPK models are mechanistic, multi-compartment frameworks that simulate the absorption, distribution, metabolism, and excretion (ADME) of a compound across organ systems. The proposed architecture is engineered to scale localized chip-level readouts into whole-body systemic biodistribution predictions by parameterizing PBPK models with computationally derived cellular toxicity signals. This is intended to provide a scientifically plausible, mechanistically grounded bridge from *in-vitro* cellular observation to systemic Phase II prediction.

Quantitative Systems Pharmacology (QSP) Modeling

QSP models integrate pharmacokinetic and pharmacodynamic data with biological network models to simulate drug effects at the systems level. The proposed architecture is designed to couple PBPK outputs with QSP frameworks to simulate multi-organ interactions, clearance rates, and off-target toxicity profiles across computationally generated synthetic patient cohorts. These generative computational cohorts are engineered to simulate whole-body biodistribution, providing statistically grounded predictions pending future physical validation.

Proposed Bypass of Legacy Animal Testing

The pipeline, as proposed, is engineered to provide a scientifically defensible computational pathway that reduces reliance on legacy animal models for pre-clinical toxicity screening. By grounding *in-silico* predictions in human-derived microphysiological data — rather than cross-species extrapolation — the architecture is intended to accelerate the timeline for golden standard testing and improve the translational fidelity of pre-clinical safety assessments. This pathway is submitted for rigorous peer review and is not presented as a validated replacement for any currently mandated regulatory testing protocol.

LOCALIZED CELLULAR TOXICITY LOSS GRADIENT (ORGAN-ON-A-CHIP READOUT)

$$\nabla W_{\mathcal{L}} = \frac{\partial \mathcal{L}}{\partial W}$$

Where $\mathcal{L}$ denotes the localized loss function derived from cellular viability readouts at the chip level, and W represents the model weight parameters being updated by the empirical biological signal.

FDA Alignment Note: PBPK and QSP models are established, FDA-accepted frameworks for mechanistic bridging. The proposed contribution of this architecture is the automated, federated coupling of patient-derived chip-level empirical readouts to these systemic models at scale — a capability intended for future in-vitro validation and not yet physically deployed.

Submit a Technical Interrogation

This vault is an open architectural audit. Qualified biostatisticians, regulatory scientists, cryptographers, and compliance architects are invited to stress-test any proof presented here. If you identify a mathematical inconsistency, a regulatory gap, or a structural vulnerability not addressed in this document, the AI Methods Producer is standing by.

Or reach us directly at **contact@rzst.org**